Breaking News
Sort by:
Top Post
Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and […]
Clarivate Identifies Fifteen Potential Blockbuster Drugs in Annual Drugs to Watch Report
Clarivate, a global leader in providing trusted information and insights to accelerate the pace of […]
Jnana Therapeutics Announces FDA Clearance of IND Application for JNT-517 for the Treatment of Phenylketonuria
Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug […]
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
Acorda Therapeutics has announced that on December 31, 2022 it entered into a new long-term […]
Sustained Therapeutics Advancing Clinical Trial for Novel Drug Delivery Platform
A Vancouver-based therapeutics company, Sustained Therapeutics, has received regulatory approval to begin the second Phase […]
Orbit Discovery and SanegeneBio Collaborate to Identify Targeting Peptides for RNAi Drugs
Orbit Discovery, a leader in the discovery of therapeutic peptide hits, has announced it has […]
IntoCell Enters into Development and License Option Agreement with ADC Therapeutics
IntoCell has announced the signing of a Material Transfer Agreement (MTA) with option to license […]
Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders
Sosei Group Corporation, the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design […]
Zhongchao Announces Drug Distributorship in China of Indian Generic Drugs of Natco Pharma
Zhongchao, a platform-based internet technology company offering services to patients with oncology and other major […]
ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo has announced that the European Medicines Agency (EMA) has validated the Type II […]
Legend Biotech Announces Acceptance of Its New Drug Application (NDA) for Ciltacabtagene Autoleucel (Cilta-Cel) in China
Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more